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Autosomal dominant polycystic kidney disease in Toronto. This study
describes the Toronto, Ontario experience with autosomal dominant
polycystic kidney disease (ADPKD). Patients were divided into three
groups: Group 1, 19 families studied with genetic markers; Group 2, 80
pre-dialysis ADPKD patients followed by Toronto nephrologists in
whom the incidence of non-renal complications and the mean age of
onset of symptomatology is documented; Group 3, 4,449 individuals
who entered end-stage renal failure (ESRF) in the Toronto region
between the years 1981 and 1992, 320 with ADPKD and 4129 with other
diseases. In this third group age of onset of ESRF, frequency, age and
cause of death is compared between ADPKD and non-ADPKD.
ADPKD caused by a gene different from that linked to chromosome 16
short-arm probes occurred at a frequency of between 8 and 17%.
Incidence of hepatic cysts in ADPKD was similar to that of previous
series, other organ involvement was underdiagnosed without deliberate
screening, and incidence of symptomatic intracranial aneurysm was
1.25%. A 5% excess of patients with ADPKD died of cerebro-vascular
accident. Years of survival after ESRF measured by life table analysis
was significantly greater for ADPKD patients than for non-ADPKD
patients. A high frequency of death due to infection still exists in
ADPKD despite the reduction of invasive procedures in diagnosis and
treatment, and despite the presumably improved recent methods of
managing infection. The average age of onset of ESRF has been delayed
by over six years, and average age of death of ADPKD patients at 63.9
years-old by 12.4 years since 1960.
Autosomal dominant polycystic kidney disease (ADPKD) is
inherited as a Mendelian autosomal dominant trait, with the
children of affected individuals having a 50% chance of inher-
iting the gene associated with the condition. This very common
illness is estimated to affect 1 in 400 to 1 in 1,000 people,
comprising as many as 600,000 individuals in the United States
[1, 2]. The gene has an apparent mutation rate of 6.5 X lO to
10 x 1O [31. In Ontario, Canada, with a population approach-
ing 3,900,000 people, 3,900 persons would be expected to have
ADPKD. An estimated 50% of these will progress to end-stage
renal failure (ESRF) and will contribute approximately 9% of
new ESRF patients per year.
Patients with ADPKD are at risk of developing other mani-
festations as well as ESRF. These include hypertension, uri-
nary tract infections, hematuria, proteinuria, extrarenal cysts,
cerebral aneurysms, cardiac valve involvement, renal calculi
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and gastrointestinal diverticuli [4-14]. Descriptions of the nat-
ural history of the disease are found in a large pre-dialysis era
study [15, 16] and in several publications by Gabow and
colleagues [17—20].
The gene presumed to be involved in the occurrence of the
majority of cases of ADPKD (locus PKD1) was localized in
1985 to the short arm of chromosome 16 in families of northern
European descent [21, 22]. Since then a number of papers and
abstracts have appeared refining the genetic map of the region
containing PKD1 and demonstrating that at least one other gene
is associated with the presentation of this disease [23—30]. The
genetic heterogeneity was first noted in two families of Italian
origin [26, 27], suggesting a possible founder effect. Later a
Danish family was noted to lack linkage to the PKD1 region [28]
and two Newfoundland families gave data strongly suggestive
of lack of linkage [29]. Some results have suggested that the
unusual genetic form(s) of ADPKD might be associated with a
less aggressive progression [28—30]. The locus name PKD3 has
been reserved for this second type of ADPKD by the Human
Gene Mapping Nomenclature Committee [41].
The experience of ADPKD in Toronto, Ontario is reviewed in
this paper. Group 1 contained 19 families who have been
studied with genetic markers to test for genetic heterogeneity of
the disease in the Ontario population.
Group 2 included 80 ADPKD patients obtained from Toronto
nephrologists, utilizing a structured questionnaire. Data from
this group was studied for the incidence of non-renal complica-
tions and the mean age of onset of symptomatology.
Finally, group 3 comprised 4449 individuals who entered
ESRF in the Toronto region between the years 1981 and 1992.
Of these patients 320 reached ESRF because of ADPKD and
4129 due to other conditions. Comparisons were made between
the two groups for many parameters including age of entry into
dialysis, frequency of death, mean age at death for those who
died, and cause of death for those who died.
Methods
Group 1 included 132 individuals from 19 families with
ADPKD referred by two Toronto area nephrologists (JMR and
MS). All participants gave informed consent. DNA from these
individuals was studied with two DNA probes previously
shown to flank the gene for the usual form of ADPKD (PKD1).
The 0alpha3'HVR.64 probe, detecting a linked DNA marker in
a chromosome location with markedly different sex-specific
recombination rates, maps 8 map units distal to the PKD1 gene
1101
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in males and 1 unit distal to the PKD1 gene in females. The
alpha3'HVR.64 probe was supplied by Professor D.J. Weath-
erall (Oxford University, Oxford, UK) [21]. This probe was
previously called 3'HVR since it originated from the 3' hyper-
variable region of the alpha I chain of the hemoglobin gene
(HBA1). The probe 24-1 (D16S80), which detects a polymor-
phism 4 map units proximal to the PKD1 gene in males and 0.5
map units from this gene in females, was donated by Dr. M.H.
Breuning (Rijksuniversiteit, Leiden, the Netherlands) [24]. A
subset of group 1 was studied with an additional five probes
purchased from Collaborative Research Incorporated (CR1,
Bedford, Massachusetts, USA) [23]. The five probes were
CRI-090 (locus D16S45), CRI-0129 (D16S56), CRI-0133
(D16S58), CRI-0136 (D16S6O) and CRI-0327 (D16S63).
DNA was extracted from blood samples obtained from co-
operating individuals and investigated for restriction fragment
length polymorphisms (RFLPs) by standard methods of restric-
tion enzyme digestion, separation of fragments by agarose gel
electrophoresis, blotting unto nylon membranes, hybridization
to the radioactively-labeled DNA probes and detection of the
separated restriction fragments by autoradiography [30]. The
pattern of inheritance of the restriction fragments in each family
was defined by inspection. Where appropriate, standard meth-
ods of statistical linkage analysis were used. Linkage analysis
methods included pairwise lod scores [31] using the computer
program LIPED [32].
The probability that an individual at risk for ADPKD will be
diagnosed as having ADPKD increases with the individual's
age. Therefore a statistical correction for errors due to variation
in age of onset of the ADPKD was incorporated into the
analysis [33]. This straight line age of onset correction used the
probabilities of at-risk individuals actually carrying the ADPKD
gene calculated by Bear et al [34] for different age groups. These
probabilities are: 0.34 for the age interval 15 to 20 years; 0.14 for
the interval 20 to 30 years; and 0.05 for the interval 30 plus
years. Penetrance (the probability that an individual who car-
ries the disease gene will be diagnosed as being affected) was
considered to increase linearly from a value of 0.05 at birth to
0.99 at 40 years of age or older. The gene frequency of ADPKD
was assumed to be 0.008.
The lod score is a measure of the relative odds in favor of
linkage versus no linkage at different arbitrarily-chosen recom-
bination values (0) between 0 and 50%. The absence of linkage
is equivalent to a recombination value of 50%. The odds values
are expressed logarithmically (to the base ten) and are therefore
called lods, an abbreviation for the term "logarithm of the
odds." The best estimate of the recombination frequency
between two linked loci (maximum likelihood method) is taken
to be the recombination value at which the lod score is
maximal. Linkage is considered to be present when the lod
score is +3 (odds 1000:1 in favor of linkage) in cases where
there is no prior reason to believe that linkage should be
present. Linkage of an ADPKD locus to the studied chromo-
some 16 markers has been demonstrated previously in a large
number of families [2 1—25]. Linkage is excluded when the lod
score is —2, (odds in favor of linkage 1:100) and the data are
inconclusive when the lod score is between —2 and +3.
To more efficiently use data from three or more loci, data
were also analyzed by a multilocus linkage analysis method, the
LINKMAP program of the LINKAGE package of programs
[35, 36]. This method varies the position of one locus (here the
ADPKD locus) over a fixed map of the linked markers to detect
the most likely position of the variable marker. The age of onset
was also corrected for LINKMAP, here as a step function,
based on the different liability classes described previously by
Bear et al [34].
Group 2 data were obtained from the outpatient charts of 80
patients diagnosed with ADPKD, obtained from about two
thirds of Toronto nephrologists actively engaged in clinical
practice. These nephrologists were selected solely by their
agreement to participate in the study after telephone or letter
contact by the investigating nephrologist (JMR). These nephrol-
ogists were associated with four of the major University of
Toronto affiliated hospitals: Saint Michael's Hospital, Sunny-
brook Hospital, the Toronto Hospital, or the Wellesley Hospi-
tal. Diagnostic testing was performed at all of these hospitals.
One patient from group 1 was also contained in group 2. The
charts were reviewed by a medical student (A.W.). Chart
review was performed utilizing a simple, structured abstraction
data collection instrument designed by A.W. and J.M.R. The
instrument was a questionnaire containing queries formatted to
be answered yes or no. The questions searched for infonnation
concerning hypertension, non-renal manifestations such as he-
patic cysts, cardiac valve malformations, and disease symptom-
atology such as abdominal fullness or dysuria or increased
urinary frequency. The presence or absence of flank pain was
assessed.
Classification of a structure as a cyst was based on palpation
at clinical examination or on a written radiologist's report. The
radiological criterion for a cyst was that it showed through
transmission of the ultrasonic beam on ultrasound. Cysts could
be detected at less than one millimeter in size. In the ovary
structures under 2.5 centimeters were not classified as cysts,
unless more than two were present, to avoid confusion with
ovarian follicles. Vaginal probes were not used for the ultra-
sound examination.
Radiological diagnosis of renal calculi was based on acoustic
shadowing.
Signs and symptoms of cardiac valve involvement assessed
included mitral valve prolapse murmur, chest pain, cardiac
arrythmia, aortic insufficiency, aortic regurgitation murmur
and/or echocardiogram.
Symptommatic intracranial aneurysm was defined as presen-
tation with symptoms of subarachnoid hemorrhage followed by
definitive investigation.
Diagnostic criteria for hypertension included blood pressure
measurement of 140/90 on repeated measurements. Uncon-
trolled hypertension was defined as blood pressure in the
hypertensive range on at least three separate occasions. Pa-
tients being maintained on antihypertensive medication were
defined as hypertensive, regardless of present blood pressure
value.
The data were stored and analyzed on an IBM compatible
personal computer using the database software program DBase
IV (BORLAND, Scotts Valley, California, USA). Simple math-
ematical means and percentages were calculated.
Data from patients in group 3 were collected by the Toronto
Region Dialysis Registry, and included information on 4449
individuals who entered ESRF in the Toronto region between
the years 1981 and 1992. Of these patients 320 had reached
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ESRF because of ADPKD and 4129 due to other conditions.
The Toronto Region Dialysis Registry was begun in 1981 to
collect and to analyze information pertaining to the dialysis
population of Metropolitan Toronto. Originally funded by the
Kidney Foundation and industry, it is now part of the regional
Multiple Organ Retrieval and Exchange (M.O.R.E.) Program.
The database receives information from all chronic dialysis
programs in the Greater Toronto (Central East Ontario) region.
These include: Credit Valley Hospital, Hospital for Sick Chil-
dren, Oriuia Soldiers' Memorial Hospital, Oshawa General
Hospital, Riverdale Chronic Care Hospital, Sheppard Centre
Self Care Dialysis Unit, St. Joseph's Health Care Centre, St.
Michael's Hospital, Sunnybrook Health Science Centre, The
Toronto Hospital (General and Western Divisions), and The
Wellesley Hospital.
The Toronto Region Dialysis Registry collects sociodemo-
graphic and medical data on all patients entering end-stage renal
disease (ESRD) programs. Patients with acute renal failure are
not included. An initial registration form is completed by the
attending nephrologist or nurse for each new patient. The
information requested includes primary renal disease diagnosis,
renal biopsy results, if any, and risk factors present at the time
renal replacement therapy is initiated. The risk factors section
requires an indication of whether or not other medical condi-
tions which may adversely affect the patients' prognosis are
present (yes or no). Such conditions include coronary artery
disease, a history of cigarette smoking, pulmonary edema,
congestive heart failure, diabetes mellitus, cerebro-vascular
accident, peripheral vascular disease, malignancy, chronic ob-
structive lung disease, hypertension, and any other serious
illness (specified) that would shorten life expectancy to less
than five years.
Regular follow-up demographics are completed by nephrol-
ogy nurses in each dialysis program, providing up-to-date
information on new patients, changes in treatment, transfers
between programs, deaths, transplants, and allograft failure.
Primary cause of death is reported using codes based on the
coding system of the Canadian Organ Replacement Registry.
Specific causes of death are categorized as cardiac, vascular,
infection, liver disease, gastrointestinal, treatment stopped,
other specified causes, and undetermined. Cardiac causes of
death, for example, include: myocardial ischemia and infarc-
tion, cardiac arrest due to hyperkalemia, hemorrhagic pericar-
ditis, cardiac arrest due to hypokalemia, cardiac arrest due to
fluid overload, cardiac arrest—cause unknown, hypertensive
cardiac failure, other causes of cardiac failure. Cerebro-vascu-
lar accident (CVA), which is included in the vascular category,
is reported separately in this paper because of the incidence of
death from CVA among ADPKD patients.
Twenty-two of the 80 patients in group 2 had reached ESRF,
and are included in group 3. These have been analyzed sepa-
rately from the entire group 3 block for issues addressed in both
groups 2 and 3 to see if they agree with group 3 as a whole. Nine
individuals from eight families in group 1 were also included in
group 3.
Data were analyzed by inspection, and the relevance of any
apparent differences between groups was assessed by the
Student's t-test or a comparison analysis [37]. A life table
survival analysis procedure (the LIFEREG procedure) was
Table 1. Summary of DNA restriction fragment length polymorphism
(RFLP) studies on ADPKD families using the DNA probe
a1pha 3'HVR
Families Individuals
Structure incomplete or inappropriate 4 6
Sporadic case 2 6
DNA uninformative 1 11
Informative 12 109
Total 19 132
performed to analyze lengths of survival after ESRF between
ADPKD and non-ADPKD patients [37].
Results
Table 1 illustrates the results of genetic analysis of 19
ADPKD families (132 individuals; group 1) with chromosome
16 linked probes. As expected because of its large number of
possible polymorphic fragments, the most informative marker
in our families was alpha3'HVR.64. Twelve of the 19 families
(63%), comprising 109 individuals, were fully informative for
genetic analysis using alpha3'HVR.64. Seven families (37%)
were not informative for the following reasons: (a) linkage
phase could not be assigned in six families (32%) either because
of incomplete or inappropriate family structure (4 of the 6
families; 21.1%), the occurrence of the ADPKD in one individ-
ual only (sporadic case; 2 of the 6 families; 10.5%); and (b) in
one family (5.3%) the DNA marker was uninformative, that is,
the patient was homozygous for the marker. Of the twelve
families informative for linkage, ten (83%) showed results
compatible with linkage of ADPKD to the DNA markers.
One family gave results suggesting that the ADPKD segre-
gating in its members was not linked to the chromosome 16
probes used. This family was studied extensively with all seven
RFLP probes, three of which were sufficiently informative for
statistical linkage analysis. Pairwise lod scores between
alpha3'HVR.64 and ADPKD and between CRI-090 and
ADPKD excluded linkage in this family at recombination frac-
tions of up to 0.06 and 0.05, respectively. The lod score was
inconclusive for linkage between CRI-0136 and the ADPKD
locus. Multipoint linkage analysis by LINKMAP excluded the
ADPKD locus from 0.20 morgans from the distal side of
alpha3'HVR.64 to 0.43 morgans on the proximal side when
alpha3'HVR.64 was arbitrarily set at 0.00. This is the genetic
interval containing the PKD1 locus. These results were sup-
ported when the data were analyzed using only affected family
members (to reduce the risk of error due to misclassification of
affected members as unaffected because they were too young to
manifest the disease). In this case even with the reduced
numbers of family members analyzed, the lod equivalent at
—2.32 with 0 = 0 between ADPKD and alpha3'HVR.64
excluded linkage. The lod equivalent between CRI-090 and
ADPKD was —1.67 and between CRI-0136 and ADPKD was
—1.78, strong evidence against linkage in both cases. The lod
equivalent never rose above —1.58 over the whole region
analyzed using affected family members only, strongly suggest-
ing no linkage with the ADPKD locus over this PKD1 contain-
ing region. This family has been reported elsewhere in greater
detail [30].
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Table 2. Comparison of the frequency of systems involvement in
ADPKD between a literature summary 19] and the Toronto study
System Literature Toronto study
Genitourinary
Kidney 100% 99%
Ovary Unknown 13%
Gastrointestinal
Hepatic 40—60% 46%
Pancreatic Rare 0%
Diverticulae 83% 4%
Cardiovascular
Valvular 30% (Echo) 5%
Intracranial aneurysm 0—40% (10%) 1.25%
Data are expressed as percent of patients studied. The probe was
a1pha 3 'HVR.
The results from one final family suggested an absence of
linkage to the genetic markers, but this latter family could not
be studied further. The presence of these two families in our
population suggests that the frequency of an additional gene or
genes for ADPKD is from 8 to 17% in our population.
The frequency of sporadic or non-familial cases, possibly
resulting from new mutation, in our population was 2 of 19 or
10%. All surviving family members of one of these individuals,
including his parents, sibling, and his grandmother had negative
abdominal ultrasound examinations. Formal paternity testing
for this case was not performed, but the RFLP results from
probe alpha3'HVR.64 were in agreement with paternity as
stated by the family. Interestingly, this patient also was diag-
nosed to have an adult form of cystic fibrosis for which there
was again no family history.
Analysis of charts from group 2, which included mainly
pre-ESRF (predialysis) patients (58 of 80 or 72.5%) to determine
the frequency of systems involved in ADPKD showed kidney
involvement in 99% of cases (Table 2) (The single exception
was a brother of an individual with extensive kidney and liver
cysts who himself had multiple liver cysts but no discernable
kidney involvement). Thirteen percent of females (3 of 23)
examined by ultrasound (US) or by US and computed tomog-
raphy (CT) had ovarian cysts detected. Thirteen of the women
studied were 50 years of age or greater at time of CT (postm-
enopausal) and none of these patients had cysts. Timing of the
study in relationship to the woman's menstrual cycle and
hormone replacement status in the postmenopausal women was
not known.
Involvement of the gastrointestinal system was frequent.
Forty-six percent (32 of 67) of patients examined by US or by
US and CT, had hepatic cysts, some with severe involvement.
One patient examined by CT only, had a negative result.
Thirty-two patients examined by US were stated to have no
liver cysts. Four patients with no liver cysts had no US or CT.
When males and females were analyzed separately, only 41.3%
(19 of 46) of males had hepatic cysts compared to 56.5% (13 of
23) of females = 1.4; P = 0.23; NS). The mean age of all 32
patients (males and females) with hepatic cysts was 38.8 12.3
years in Toronto versus 42.3 2.0 years in a recently published
series [19]. The mean age of those without cysts was 36.3 15.9
years in Toronto against 32.5 1.4 years in the study by Gabow
and Schrier [19]. The mean age of females with cysts was
slightly younger (37.8 11.4 years) compared to males (39.4
Fig. 1. Status of Toronto Area ADPKD () and non-ADPKD ()
patients with end-stage renal disease, obtained from the Toronto
Region Dialysis Registry expressed as percent of total patients in the
group.
13.2 years; NS). The overall male/female ratio in the present
group was 1.5 or 19 males versus 13 females. The mean age of
females with cysts was higher than that of females without
hepatic cysts (37.8 11.4 vs. 28.5 14.9 years; NS). No
pancreatic cysts were noted in group 2 patients. Symptomatic
intestinal diverticulae were noted in 4% of group 2 patients.
Renal calculi were recorded in 8 of 80 (10%) of patients. Five
percent of ADPKD patients had clinically apparent cardiac
valve involvement.
Symptomatic intracranial aneurysm occurred in 1.25% of
these patients.
Chart inspection demonstrated that most asymptomatic pa-
tients were not screened either by recorded systems review or
by formal objective testing for intracranial aneurysm, cardiac
valvular lesions or intestinal diverticulae. In fact, the only
clinical test used in the majority 67 of 80 (84%) of patients was
abdominal ultrasound. This examination gave objective data on
the presence or absence of cyst occurrence in different organs.
Demographic data were analyzed for group 3. The status of
the two types of ESRF patients (ADPKD and non-ADPKD
patients) is shown in Figure 1. Equivalent proportions of
patients in each group remained on dialysis or died. However,
about 29% of ADPKD patients have received a functioning
transplant versus 21% of non-ADPKD patients ( = 8.582; P =
0.003). Two percent of non-ADPKD patients have recovered
renal function and, not surprisingly, none of the ADPKD
patients have done so. Six to seven percent of patients were lost
to follow-up in both groups.
The mean age at entry into ESRF for the 320 patients with
ADPKD was older (54.4 10.9 years) than for the 4,129
non-ADPKD patients (50.4 19.4 years; P = 0.0001 by t-test;
Fig. 2). The mean age at entry into ESRF for patients with
ADPKD of the type not linked to the chromosome 16 probes
(PKD3) was much higher: 69.5 years (a difference of + 15.2
years). This average age, however, was derived from only two
patients. Mean age of entry into ESRF did not differ with or
without hypertension. Sixty-four percent (205) of the 320
ADPKD patients with ESRF suffered from hypertension and
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entered ESRF at a mean age of 54.9 11.0 years. Thirty-six
percent had no hypertension and entered ESRF at mean age
53.5 10.5 years).
Thirty-five percent (113) of the ADPKD patients died during
the reporting period versus 38.4% (1708) of the non-ADPKD
patients (Fig. 3). The average age at death was 63.9 8.5 years
for ADPKD versus 62.1 14.8 years for the 1,708 non-ADPKD
patients (P = 0.05). When the one ESRF patient whose
ADPKD was known to be of the PKD3 type was dropped from
the analysis, the average age of death remained unchanged at
63.9 8.5 years. None of six other ESRF patients whose
families were studied with DNA probes (in group 1) and whose
disease was apparently linked with the chromosome 16 probes
died. Their average age at time of study was 59.8 years. An
additional individual from group 1 had ESRF. This family's
results suggested PKD3 type ADPKD but could not be further
studied. This person was 56 years old. Years of survival after
ESRF measured by the LIFEREG procedure was significantly
less for non-ADPKD than ADPKD patients ( = 7.794; P =
0.005; Fig. 4A). The significance of this difference was lost
when patients suffering from diabetes were dropped from the
analysis (y = 1.166; P = 0.28), although the ADPKD patients
still appeared to show a longer survival than the non-ADPKD
patients (Fig. 4B). The leading cause of death in both groups
was cardiac (34% in ADPKD, 42% in non-ADPKD; x2= 2.68; P
= 0.10), however, a significantly increased incidence of death
from CVA (11%) in ADPKD versus non-ADPKD (6%; , =
4.450; P = 0.04) and infection (20.4% ADPKD vs. 12.5%
non-ADPKD; A2 = 5.839; P = 0.02) was observed (Table 3).
Only four of twelve ADPKD patients (3 3%) who died of CVA
also suffered from hypertension compared to 69 of 98 non-
ADPKD patients (70.4%), suggesting that a significant number
(up to 66%) of ADPKD patients who died of CVA did not die of
"stroke" secondary to hypertension. The age at death of
ADPKD patients with CVA and hypertension was 60.7 5.8
years, significantly younger than the age of non-ADPKD pa-
tients with CVA and hypertension (64.3 11.4 years (, =
6.583, P 0.01). The remaining CVA patients in the ADPKD
group were eight persons (66%) without hypertension who died
at a mean age of 66.6 9.3 years. In the non-ADPKD group 29
individuals (29.6%) were without hypertension and died at a
mean age of 59.9 years.
Table 4 classifies the deaths due to infection by infectious
subtype. No one particular type of infection explained the
increase of death due to infection. Rather, each subclass of
bacterial infection showed a slight increase in the ADPKD
patient population.
Discussion
The incidence of Ontario ADPKD patients whose disease
shows genetic linkage to the chromosome 16, by short arm
probes which have been previously linked to ADPKD in
Europe, is at least 83%. In at least 8% and possibly up to 17%
of Ontario families with ADPKD, the disease is not linked to the
previously reported probes (PKD3). One of the families, in
whom genetic linkage to chromosome 16 markers did not occur,
was studied extensively to prove the absence of genetic linkage
and has been reported elsewhere [30]. This finding confirms the
discovery of genetic heterogeneity published in previous re-
ports [26—30], demonstrates its presence in an additional popu-
lation group, and assists in refining a frequency estimate for the
alternate (PKD3) gene(s).
Age at entry to ESRF has changed since 1957 for ADPKD
patients. In Dalgaard's 1957 study [15, 16] the average age at
death was 51.5 years, and death was said to occur about three
years after onset of uremia, putting onset of uremia at an
average age of 48.5 years. The mean age at onset of ESRF in
1982 to 1992 was 54.4 10.9 years for ADPKD patients.
Therefore it is fair to conclude that patients from 1981 to 1992
may lose their renal function about six to seven years later
compared to those in 1957. This improvement may result from
better hypertension control and/or better control of infection. In
addition, the geographic isolation from Dalgaard's (Danish)
group may influence the difference in age of onset of ESRF in
the present study group, either having allowed the accumula-
tion of different intragenic or extragenic mutations influencing
ADPKD in the present population, or allowing interaction of
different environmental variables with the original ADPKD
60%
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Fig. 2. Age at entry to end-stage renal failure in years for ADPKD (•)
and non-ADKPD () patients, obtained from the Toronto Region
Dialysis Registry.
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Fig. 3. Age at death for ESRF patients who died, obtained from the
Toronto Region Dialysis Registry. Symbols are: (•) ADPKD patients;(n), non-ADPKD patients.
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Fig. 4. Survival curves forADPKD (+) and
non-ADKPD (..-) patients after ESRF
graphed as percent survival versus years after
ESRF, generated by life table analysis from
the Toronto Region Dialysis Registry. (A)
Data including all patients in both groups. (B).
Data excluding patients with diabetes from
both groups.
Table 3. Comparison of causes of death between patients who had
ADPKD and diseases other than ADPKD (Non-ADPKD) from 1981—
l992
Cause of death ADPKD Non-ADPKD
Cardiac 34% 42%
Vascular 1% 3%
CVA 11%b 6W'
Infection 20%b 12%b
Gastrointestinal 4% 2%
Liver disease 0% <1%
Other causes 12% 14%
Undetermined 10% 10%
Treatment stopped 10% 12%
a Data obtained from the Toronto Region Dialysis Registry and
expressed as percent of total deaths in each group (ADPKD = 113;
Non-ADPKD = 1708)b Significant differences between ADPKD and Non-ADPKD when
analyzed by
mutation(s) in the present population. Actual age of death in the
ADPKD population, with all treatment improvements, includ-
ing dialysis, is at a mean of 63.9 years or more than a decade
(12.4 years) later than in 1957.
Of 320 patients with ADPKD, 205 had hypertension at the
beginning of treatment for ESRF (64.1%). There was no differ-
ence in age at entry to ESRF or in age at death from all causes
in patients with or without hypertension.
The incidence of hepatic cyst involvement is similar to that of
previous series [19]. As noted in other studies, females seem to
be more at risk for hepatic involvement and the frequency of
hepatic cyst involvement tends to increase with age.
The frequency of involvement of other organ systems (such
as cardiovascular and gastrointestinal) was much lower than
that reported at other centers [17—19]. However, specific sen-
sitive screening tests were used in the other centres to assess
the presence of such involvement. The patients reported here
were assessed symptomatically only. We infer therefore that
the incidence of other organ involvement is underdiagnosed
without deliberate screening.
Eleven percent of patients with ADPKD died of cerebrovas-
Table 4. Comparison of specific infections causing death between
patients who had ADPKD and diseases other than ADPKD
(Non-ADPKD) from 1981—1992
Type of Infection ADPKD Non-ADPKD
Peritonitis 2.7% 1.5%
Septicemia 12.4% 8.3%
Bacterial pulmonary 1.8% 1.2%
Viral pulmonary 0.0% 0.4%
Fungal pulmonary 0.9% 0.2%
Tuberculosis 0.0% 0.1%
Generalized viral 1.8% 0.3%
Other infections 0.9% 0.5%
Data are expressed as the percent of total deaths in each group
(ADPKD = 113; Non-ADPKD = 1708).
cular accident (CVA). This was a five percent greater incidence
than that in non-ADPKD patients. It is known that patients with
ADPKD have an increased incidence of intracranial aneurysm
and this extra five percent dying of CVA may represent
ruptured intracranial aneurysms. This possibility is substanti-
ated by the fact that only 1/3 of those dying of CVA in the
ADPKD group suffered from hypertension. In addition, age at
death of those dying of CVA with hypertension in the ADPKD
group was significantly lower than that of those dying of CVA
with hypertension in the non-ADPKD group. Previous work
with decision analysis has suggested that the general medical
risks of diagnostic cerebral angiography have outweighed its
diagnostic benefits [38] for ADPKD patients. New information
suggests that patients with ADPKD may have an even higher
risk of such medical complications than the general population
[11]. The development of the non-invasive techniques of high
resolution computed tomography and magnetic resonance im-
aging [8, 11] allows diagnosis of aneurysms above 6 mm in size,
which are more likely to rupture [39, 40]. We believe that all
patients with ADPKD should be screened with high resolution
computed tomography and/or magnetic resonance imaging in an
effort to diagnose aneurysms at an earlier, treatable stage [8].
Since the deaths due to CVA in the ADPKD group occurred at
an average age of 60.7 5.8 years in the hypertension group
A B
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and 66.6 9.3 years in the non-hypertension group, we believe
that this screening of ADPKD patients should continue well
into the seventh decade. We believe that the greatest "at risk"
period for aneurysm rupture is in the 55 to 65 year age interval
in the presence of hypertension, and possibly somewhat later in
individuals who do not suffer from hypertension. The 11%
incidence of death due to CVA has not changed dramatically
since the predialysis era reports [14, 15] which noted 13% of
deaths caused by CVA, 59% due to uremia, 6% to cardiac and
22% from other causes including infection. A high incidence of
death due to infection still persists in ADPKD patients (20.4%
vs. 12.5% in non-ADPKD ESRF patients). The increase of
infectious deaths in ADPKD versus non-ADPKD patients is not
solely a result of peritonitis or of graft infections but is actually
a result of a general increase in all types of infections reported
for the ESRF group. A review of the literature on infection in
the ADPKD patients reveals case reports of single rare atypical
infections in ADPKD patients [11—13]. These interesting obser-
vations suggest that the spectrum of involvement of ADPKD
organ systems may also include an immunodeficiency defect.
This possibility will be investigated in future studies.
In summary, ADPKD is a significant cause of renal failure in
the Toronto population. Most of these families with ADPKD
appear to have a disease linked to genetic markers on the short
arm of chromosome 16 (PKD1). These markers could therefore
be used for preclinical diagnosis of the condition in those
families which are linked or in screening prospective, related
organ donors in individual families. A number of complications
can arise in patients with ADPKD including hepatic cysts, CVA
and infections. The age of entry to ESRF and the age of death
appears to have been delayed by over twelve years with modem
methods of treatment.
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